Björn Hock

Björn Hock is the current Scientific Advisor at Tubulis. Björn has also served as the VP Biologics Technologies and Development at Ferring Pharmaceuticals from August 2017 to September 2021. Prior to that, they were the Senior Dirctor, Antibody Drug Conjugates and Targeted NBE Therapeutics at Merck KGaA, Darmstadt, Germany from February 2016 to April 2017. Before that, they were the Director, Global head Protein Engineering and Antibody Technologies at Healthcare Business of Merck from August 2010 to May 2017. Björn has also served as the Director, Protein Engineering and Antibody Technologies at Healthcare Business of Merck from August 2010 to January 2016. Additionally, they were the Dirctor, Binders and Protein Engineering at Healthcare Business of Merck from November 2008 to July 2010.

Björn Hock has a private teaching position in biochemistry at the Technical University of Darmstadt, a doctorate in biochemistry from the Chemotherapeutic Research Institute Georg Speyer House, and a diploma in biochemistry from the Johann Wolfgang Goethe-Universität Frankfurt am Main.